missing translation for 'onlineSavingsMsg'
Learn More
Learn More
STEMCELL Technologies LY2228820 (Dimesylate)
Description
- LY2228820 is a trisubstituted imidazole derivative and a potent inhibitor of the α- and β-isoforms of p38 MAP kinase (MAPK) in vitro (IC50 = 5.3 and 3.2 nM, respectively) with anti-inflammatory and anti-neoplastic activities (Campbell et al.) This product is supplied as the dimesylate salt of the molecule
- Combined with other small molecule inhibitors such as Rapamycin (Catalog #73362) and SR1 (Catalog #72342; Li et al.) or SB203580 (Catalog #72222), Vx702, and BIRB-796 (Catalog #72682), enhances the self-renewal of cord blood-derived hematopoietic stem cells (Baudet et al.)
- By inhibiting p38 MAPK, which is highly expressed in human cancers, LY2228820 is potent and selective at inhibiting tumor growth in animal models of a variety of human cancers (Campbell et al.)
Specifications
Specifications
| CAS | 862507-23-1 |
| Synonym | Ralimetinib Mesylate; LSN2322600 |
| Quantity | 5 mg |
| Molecular Formula | C24H29FN6 · 2CH3SO3H |
| Purity | ≥98% |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?